Testing effectiveness (Phase 2)Ended earlyNCT03099486What this trial is testingRegorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRCWho this might be right forColorectal Cancer Fox Chase Cancer Center 2
Not applicableUnknownNCT03259009What this trial is testingRAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)Who this might be right forMetastatic Colorectal Cancer Association des Gastroentérologues Oncologues 73
Not applicableStudy completedNCT02624895What this trial is testingObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st LineWho this might be right forMetastatic Colorectal Cancer Amgen 296
Testing effectiveness (Phase 2)UnknownNCT04034459What this trial is testingFOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRCWho this might be right forMetastatic Colorectal Cancer Ludwig-Maximilians - University of Munich 109
Large-scale testing (Phase 3)UnknownNCT03909724What this trial is testingPulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)Who this might be right forColorectal CancerMetastasis Amsterdam UMC, location VUmc 60
Testing effectiveness (Phase 2)Study completedNCT01374425What this trial is testingStudy of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)Who this might be right forColorectal Cancer Genentech, Inc. 376
Testing effectiveness (Phase 2)Looking for participantsNCT05319314What this trial is testingLYL273 for Patients With Relapsed or Refractory mCRCWho this might be right forColorectal Cancer Lyell Immunopharma, Inc. 155
Not applicableUnknownNCT01756625What this trial is testingPREMIUM, Observational StudyWho this might be right forFirst Line WT KRAS mCRC Dr.Laurent Mineur 500
Not applicableStudy completedNCT02256800What this trial is testingEscalated Dose of Irinotecan in mCRCWho this might be right forMetastatic Colorectal Cancer Jaw-Yuan Wang, MD, PhD 213
Testing effectiveness (Phase 2)UnknownNCT04759664What this trial is testingLUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRCWho this might be right forEGFRI Induced Acneiform Lesions Lutris Pharma Ltd. 117
Testing effectiveness (Phase 2)UnknownNCT06379399What this trial is testingTrifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRCWho this might be right forColorectal Cancer Metastatic Wangxia LV 26
Testing effectiveness (Phase 2)UnknownNCT05292417What this trial is testingRadiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRCWho this might be right forColorectal Neoplasms The First Affiliated Hospital of Xiamen University 71
Early research (Phase 1)Ended earlyNCT04073615What this trial is testingRivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)Who this might be right forMetastatic Colorectal Cancer Elevar Therapeutics 29
Testing effectiveness (Phase 2)Study completedNCT02651415What this trial is testingPhase II Study of Perindopril and Regorafenib in mCRCWho this might be right forMetastatic Colorectal Cancer British Columbia Cancer Agency 12
Large-scale testing (Phase 3)Active Not RecruitingNCT04776655What this trial is testingStudy in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaBWho this might be right forColorectal CancerMetastatic Colorectal CancerRAS Mutation Azienda USL Reggio Emilia - IRCCS 280
Early research (Phase 1)Looking for participantsNCT05719558What this trial is testingASP1002 in Adults for Treatment of Solid TumorsWho this might be right forAdvanced Solid Tumors Astellas Pharma Global Development, Inc. 798
Testing effectiveness (Phase 2)Ended earlyNCT00642746What this trial is testingErlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)Who this might be right forMetastatic Colorectal Cancer OHSU Knight Cancer Institute 16
Large-scale testing (Phase 3)Study completedNCT04835142What this trial is testingComparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRCWho this might be right forMetastatic Colorectal Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 688
Large-scale testing (Phase 3)Ended earlyNCT04607668What this trial is testingTrilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):Who this might be right forColorectal Cancer MetastaticMyelosuppression-AdultChemotherapeutic Toxicity G1 Therapeutics, Inc. 326
Testing effectiveness (Phase 2)Study completedNCT05061017What this trial is testingPixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)Who this might be right forNSCLCMetastatic Colorectal CarcinomaRefractory Melanoma Diwakar Davar 13